HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NK 250

potentiates the action of antitumor drugs against drug-sensitive tumors; structure given in first source

Also Known As:

NK-250

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - NK 250: 1

Related Diseases

1.	Neoplasms (Cancer) 10/01/1990 - "These two 1,4-dihydropyridines, NK-250 and NK-252, are unique compounds because they were effective not only in circumventing the drug resistance, but also in potentiating the action of antitumor drugs against drug-sensitive tumors." 10/01/1990 - "We investigated whether two representative 1,4-dihydropyridine derivatives, NK-250 and NK-252, could potentiate the antitumor activity of multiple anticancer agents including vincristine (VCR), vinblastine, vindesine and actinomycin D in drug-resistant tumor cells and their parental drug-sensitive tumor cells. "
2.	Leukemia 10/01/1990 - "In chemotherapeutic experiments with leukemia-bearing mice, NK-250 or NK-252 was orally administered in combination with different drugs of the MDR phenotype administered intraperitoneally. " 10/01/1990 - "NK-250 and NK-252 at 5-10 microM almost completely reversed VCR resistance in cultured VCR-resistant P388/VCR cells derived from the mouse drug-sensitive P388/S leukemia cell line and also potentiated the cytocidal activity of VCR in drug-sensitive P388/S cells. "

Related Drugs and Biologics

1.	Vindesine (Vindesin)
2.	Vincristine (Oncovin)
3.	Vinblastine (Vinblastine Sulfate)
4.	Dactinomycin (Actinomycin)
5.	Antineoplastic Agents (Antineoplastics)
6.	NK 252
7.	1,4-dihydropyridine (dihydropyridine)